Establishment of Cancer Precision Medicine (CPM) and expansion of genomic analysis and cancer immunology businesses through a joint venture with TE
First written in FY2018-Q1. 26 of 31 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-07-09.
1 other company's latest entry also says "Advanced".
- 2026-07-09AdvancedOther Disclosures
「As a domestic contract analysis company, CPM Co. will introduce the details of this panel analysis service and its quality assurance system, among other matters.」
The disclosure presents a specific sales and service initiative for CPM Co.'s cancer precision medicine business: introducing its next-generation sequencing panel analysis service using liquid biopsy at a webinar hosted by Illumina Japan K.K., as a domestic contract analysis company. - FY2026AdvancedAnnual report
「In addition, CPM has newly introduced analytical technologies including whole-genome sequencing using long-read sequencing. Furthermore, CPM has entered into a joint research agreement with the Human Genome Center at the Institute of Medical Science, The University of Tokyo, to develop genome data analysis technologies that rapidly process the vast amounts of data obtained through long-read sequencing and other methods and organize the necessary information, with the aim of further promoting genome research and genomic medicine.」
For CPM's cancer precision medicine business, the company disclosed the introduction of whole-genome analysis technology using long-read sequencing and a joint research project on genomic data analysis with the Human Genome Analysis Center of the Institute of Medical Science, The University of Tokyo. - FY2026-H1AdvancedAnnual report
「CPM has strengthened its sales structure by entering into a partnership agreement with M.S. Techno Systems Co., Ltd. to build and operate a service providing general support for customers considering ELISPOT analysis, and a business alliance agreement with JTB Corporation for medical coordination services, including cancer gene panel testing and neoantigen therapy on a private-pay basis for foreign visitors to Japan seeking medical care.」
CPM's cancer precision medicine business strengthened its sales structure through new partnership agreements covering ELISPOT analysis support and medical coordination for foreign visitors to Japan. - FY2025AdvancedAnnual report
「Cancer precision medicine business Business revenue was ¥747 million, primarily from income received for analysis services and other services, an increase of ¥137 million from the previous fiscal year. The operating loss was ¥90 million, compared with a loss of ¥235 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services (whole-genome sequencing, neoantigen analysis and neoantigen dendritic cell therapy), liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM generated annual business revenue of ¥747 million, while its operating loss narrowed from ¥235 million to ¥90 million. - FY2025-H1WorsenedAnnual report
「Cancer precision medicine business Business revenue was ¥222 million, primarily from income received for analysis services and other services, a decrease of ¥133 million from the previous fiscal year. The operating loss was ¥93 million, compared with a loss of ¥108 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services (whole-genome sequencing, neoantigen analysis and neoantigen dendritic cell therapy), liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Revenue from the cancer precision medicine business declined from ¥356 million in the same period of the previous fiscal year to ¥222 million. Meanwhile, the operating loss narrowed from ¥108 million to ¥93 million, indicating weaker revenue growth but a reduction in losses. - FY2024AdvancedAnnual report
「To expand order capacity, we introduced new analysis equipment during the fourth quarter under review.」
In CPM's cancer precision medicine business, new analysis equipment was introduced, and the business advanced to the stage of strengthening order capacity and competitiveness by improving analysis speed and the rate of compliance with bidding requirements, among other measures. - FY2024-Q3AdvancedAnnual report
「From the third quarter of the fiscal year ending March 2024, we also began handling orders from overseas, including orders from medical institutions in Japan and overseas related to medical tourism. To expand order capacity, we introduced new analysis equipment in January 2024 and plan to begin operating it during the current fiscal year.」
CPM's business began handling overseas orders related to medical tourism, while the introduction of new analysis equipment is strengthening order capacity, analysis speed and other capabilities. - FY2024-Q2WorsenedAnnual report
「b. Cancer precision medicine-related business Revenue from the business was ¥356 million, down ¥150 million year on year, due to income received from analysis services and other sources. The operating loss was ¥108 million, compared with a loss of ¥48 million in the previous fiscal year, mainly due to the recognition of research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM saw revenue from analysis services and other services decline from ¥506 million in the same period of the previous fiscal year to ¥356 million, while its operating loss widened from ¥48 million to ¥108 million. - FY2024-Q1WorsenedAnnual report
「b. Cancer precision medicine business Business revenue was ¥147 million, primarily from income received for analysis services and other services, a decrease of ¥232 million from the previous fiscal year. The operating loss was ¥51 million, compared with operating profit of ¥9 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services (whole-exome sequencing, RNA sequencing and neoantigen analysis), liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM recorded a year-on-year decline in revenue from analysis services and other services and moved from operating profit to operating loss. - FY2023AdvancedAnnual report
「Cancer precision medicine business Business revenue was ¥1,125 million, primarily from income received for contract testing services and other services, a decrease of ¥29 million from the previous fiscal year. The operating loss was ¥34 million, compared with a loss of ¥48 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services (whole-exome sequencing, RNA sequencing and neoantigen analysis), liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM recorded annual business revenue of ¥1,125 million, and its operating loss narrowed from the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「Business revenue was ¥691 million, primarily from income received for contract testing services and other services, an increase of ¥354 million from the previous fiscal year.」
The cancer precision medicine business centered on CPM generated cumulative business revenue of ¥691 million from contract testing services and other services, an increase from the same period of the previous fiscal year. - FY2023-Q2AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥506 million, reflecting income received from analysis services and other sources, an increase of ¥263 million year on year. Operating loss was ¥48 million, compared with a loss of ¥62 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM generated revenue of ¥506 million from analysis services and other services, an increase year on year, while its operating loss narrowed. - FY2023-Q1AdvancedAnnual report
「In addition, CPM has opened an Ariake satellite laboratory as a business location within the Ariake Satellite Laboratory of the Cancer Institute, and will continue to participate in large-scale genetic analysis services.」
For CPM, the company reported the opening of a business location within the Ariake Satellite Laboratory of the Cancer Institute, as well as orders for and continued participation in whole-genome sequencing analysis under the Whole-Genome Analysis Implementation Plan. - FY2022AdvancedAnnual report
「Cancer precision medicine business Business revenue was ¥1,154 million, primarily from income received for contract testing services and other services, an increase of ¥883 million from the previous fiscal year.」
The cancer precision medicine business centered on CPM generated annual business revenue of ¥1,154 million, an increase of ¥883 million from the previous fiscal year and a substantial increase from ¥271 million in the previous fiscal year. - FY2022-Q2AdvancedAnnual report
「As announced on 18 October 2021, our consolidated subsidiary Cancer Precision Medicine obtained a large order for whole-genome sequencing analysis services.」
The company reported the receipt of a large order for whole-genome sequencing analysis services as business progress after the filing date in the cancer precision medicine business centered on CPM. - FY2022-Q1AdvancedAnnual report
「• Pathogen testing for COVID-19: nucleic acid amplification testing (saliva-based RT-PCR method (*20))」
Saliva-based RT-PCR pathogen testing for COVID-19 was added to CPM's test menu. - FY2021-Q3AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥187 million, reflecting income received from commissioned testing services and other sources, an increase of ¥38 million year on year. Operating loss was ¥233 million, compared with a loss of ¥312 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM recorded an increase in business revenue year on year and a reduction in its operating loss. - FY2021-Q2AdvancedAnnual report
「• Pathogen testing for COVID-19: nucleic acid amplification testing (saliva-based RT-PCR method (*20))」
Saliva-based RT-PCR pathogen testing for COVID-19 was added as a test item to CPM's cancer precision medicine business. - FY2021-Q1RestatedAnnual report
「Through a capital and business alliance with Theragen Bio Co., Ltd. (headquartered in South Korea; “TB”; formerly Theragen Etex Co., Ltd.), which provides global next-generation sequencing analysis services for genomes, transcriptomes and epigenomes, we established Cancer Precision Medicine Co., Ltd. (“CPM”) as a subsidiary conducting large-scale genetic testing of cancer genes and research and development into cancer immunotherapy. CPM operates a cancer precision medicine-related business.」
The cancer genetic analysis and cancer immunology business, based on the joint venture between CPM and TB, is ongoing. The partner's name has changed from Theragen Etex to Theragen Bio. - FY2020AdvancedAnnual report
「Cancer precision medicine-related business Business revenue amounted to ¥210 million, an increase of ¥134 million year on year, mainly from income received for contracted testing services. Operating loss amounted to ¥393 million, compared with a loss of ¥824 million in the previous fiscal year, mainly due to the recognition of research and development expenses relating to genetic analysis services, including whole-exome sequencing analysis, RNA sequencing analysis and neoantigen analysis, as well as liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine business centered on CPM generated annual business revenue of ¥210 million, while its operating loss narrowed from ¥824 million in the previous fiscal year to ¥393 million. The annual results showed an increase in business revenue and a reduction in losses. - FY2020-Q3AdvancedAnnual report
「Cancer precision medicine-related business Business revenue amounted to ¥148 million, an increase of ¥104 million year on year, mainly from income received for contracted testing services. Operating loss amounted to ¥312 million, compared with a loss of ¥645 million in the previous fiscal year, mainly due to the recognition of research and development expenses relating to genetic analysis services, including whole-exome, RNA sequencing and neoantigen analysis, liquid biopsy analysis services, TCR/BCR repertoire analysis services and immune response analysis services.」
In the cancer precision medicine-related business, business revenue of ¥148 million was recorded, while operating loss narrowed from ¥645 million in the previous year to ¥312 million. - FY2020-Q2AdvancedAnnual report
「As of the filing date of this document, the company had newly begun providing analysis services for whole-genome sequencing, single-cell RNA sequencing and metagenomic sequencing.」
In the cancer precision medicine business centered on CPM, the company newly began providing whole-genome, single-cell RNA and metagenomic analysis services in addition to its existing analysis services. - FY2020-Q1AdvancedAnnual report
「Cancer precision medicine-related business Business revenue amounted to ¥49 million, an increase of ¥36 million year on year, mainly from income received for contracted testing services. Operating loss amounted to ¥108 million, compared with a loss of ¥147 million in the previous fiscal year, mainly due to the recognition of research and development expenses and cost of sales relating to analysis services, including whole-exome analysis, RNA sequencing analysis, neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
In the cancer precision medicine-related business centered on CPM, revenue from contracted testing services amounted to ¥49 million, an increase year on year. Operating loss narrowed from the previous year. - FY2019-Q3AdvancedAnnual report
「Business revenue amounted to ¥44 million, mainly from income received for contracted testing services. Operating loss amounted to ¥645 million, mainly due to the recognition of research and development expenses relating to genetic analysis services, including whole-exome, RNA sequencing and neoantigen analysis, liquid biopsy analysis services, TCR/BCR repertoire analysis services and immune response analysis services.」
In the cancer precision medicine-related business centered on CPM, ¥44 million in business revenue from contracted testing services and other sources and an operating loss of ¥645 million were reported, updating the record of business operations. - FY2019-Q2AdvancedAnnual report
「Cancer precision medicine-related business Business revenue amounted to ¥22 million, mainly from income received for contracted testing services. Operating loss amounted to ¥483 million, mainly due to the recognition of research and development expenses relating to genetic analysis services, including whole-exome, RNA sequencing and neoantigen analysis, liquid biopsy analysis services, TCR/BCR repertoire analysis services and immune response analysis services.」
In the cancer precision medicine-related business centered on CPM, ¥22 million in business revenue from contracted testing services was reported, providing concrete evidence of business operations and commercialization. - FY2018AdvancedAnnual report
「In the cancer precision medicine-related business, the company made ¥439,858 thousand in capital expenditures to establish a laboratory.」
In the cancer precision medicine business centered on CPM, a clinical laboratory was newly established and ¥439,858 thousand in capital expenditures was made, giving concrete form to the business platform. - FY2018-Q3AdvancedAnnual report
「In November 2017, the company transferred its former tumor immunology analysis division to Cancer Precision Medicine Co., Ltd. through a company split (simplified company split). After completion of these procedures, the ownership ratio of CPM became 64% for the company and 36% for TE.」
For CPM, the transfer of the tumor immunology analysis business through a company split and the establishment of the ownership ratio at 64% for the company and 36% for TE progressed concretely. - FY2018-Q2AdvancedAnnual report
「CPM became a joint venture between the company and TE after TE, which provides next-generation sequencing analysis services covering global genomics, transcriptomics and epigenomics, among others, made an equity investment in and formed a business alliance with CPM. As of the filing date of this document, the company also transferred its tumor immunology analysis division to CPM through a company split (simplified company split). The division conducts research and development of cancer immunotherapies, including oncoantigens, as well as analysis services for T-cell and B-cell receptors using next-generation sequencers as an advanced initiative.」
For CPM, the formation of a joint venture through TE's equity investment and business alliance, and the transfer of the tumor immunology analysis business through a company split, progressed concretely. - FY2018-Q1First statedAnnual report
「On 24 July 2017, the company established Cancer Precision Medicine Co., Ltd. as a subsidiary to conduct large-scale genetic analysis testing for cancer and research and development of cancer immunotherapy. Theragen Etex Co., Ltd. (headquartered in South Korea; CEO: Tae Soon (Samuel) Hwang; hereinafter, TE), which provides next-generation sequencing analysis services covering global genomics, transcriptomics and epigenomics, among others, decided to make an equity investment in and form a business alliance with CPM. CPM therefore became a joint venture between the company and TE.」
CPM was established as a subsidiary with capital of ¥250 million and 500 issued shares, with TE to make an equity investment and form a business alliance. The plan was to transfer the tumor immunology analysis division through a company split and expand the business into genomic analysis, liquid biopsy, neoantigen development, and clinical applications of TCR/BCR analysis. Following completion of the procedures, the ownership ratio was to be 64% for the company and 36% for TE.